Stock Alert: TFF Pharma (TFFP) Inks Deal With Biodefense Research Organization

(RTTNews) - TFF Pharmaceuticals Inc. (TFFP) has entered into a Cooperative Research and Development Agreement, or CRADA, with the United States Army Medical Research Institute of Infectious Diseases for defensive research into countermeasures against biological warfare.

As per the agreement, the Company and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID ) will collaborate over a 3-year period to investigate Thin Film Freezing to formulate two different countermeasures, a monoclonal antibody against Alphaviruses (e.g. Venezuelan, Western, and Eastern equine encephalitis viruses) and a vesicular stomatitis virus vaccine against Filoviruses (e.g. Ebola, Marburg).

The USAMRIID will evaluate the immune responses induced by the dry powder formulations given by the pulmonary or intranasal route in a rodent model, as compared to the traditional routes of administration.

Glenn Mattes, CEO of TFF Pharmaceuticals said, "Biodefense threats and emerging infectious diseases such as COVID-19 continue to be a major concern to our military and civilian populations. There is a critical unmet need for the development of more effective vaccines, therapeutics and drug formulations to meet this threat."

TFFP has traded in a range of $3.44 to $5.60 in the last 1 year. The stock closed yesterday's trading at $4.70.